<DOC>
	<DOC>NCT00631189</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of Rosuvastatin 5 mg as an hypercholesterolemia treatment comparatively at 2 other statins: Pravastatin 40 mg and Atorvastatin 10 mg. Treatment efficacy will be evaluated by the percentage of LDL-C variation after 8 weeks of treatment.</brief_summary>
	<brief_title>Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>subjects presenting type IIa or IIb primary hypercholesterolaemia diagnosed for at least 3 months, in a context of primary prevention with at least two associated cardiovascular risk factors and: (i)either "naive" to all lipidlowering therapy, (ii)or treated with a statin (treatment ongoing or stopped during the previous 8 weeks) homozygous or heterozygous familial hypercholesterolaemia hypertriglyceridaemia (TG â‰¥ 4 g/l) subjects at high cardiovascular risk according to the AFSSAPS 2005 definition (coronary artery disease or history of documented vascular disease, high cardiovascular risk type 2 diabetes, subject in primary prevention with a 10year CHD risk &gt; 20%) history of adverse events or hypersensitivity to an HMG CoA reductase inhibitor (particularly a history of myopathy) concomitant use of any drugs not authorized during the study active liver disease with elevation of serum transaminases (ASAT, ALAT) more than twice the upper limit of normal CPK more than 3 times the upper limit of normal moderate or severe renal failure (creatinine clearance &lt; 6 ml/min) poorly controlled hypothyroidism; poorly controlled hypertension (DBP &gt; 95 mm Hg and/or SBP &gt; 180 mm Hg)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>dyslipidemia</keyword>
</DOC>